logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

mCRC: HD-irinotecan safe, more effective in patients with certain genotypes in Spanish RCT

Phase 2 trial finds ORR 73% higher and no excess severe toxicity or dose reductions.